Domestic independent research and development a new type of liver cancer diagnosis reagent 
 

September 27, 2014 

 
Source: journal of science and technology 

        After 17 years of unremitting efforts, the national science, second military medical university, director of the center for international cooperation of liver cancer hong-yang wang, director of the center for signal transduction research team, led by academician, successfully developed with independent intellectual property rights of the new type of liver cancer diagnosis reagent Glypican - 3 (hereinafter referred to as GPC3). Recently, the group and fuzhou new biotechnology development co., LTD, declare GPC3 detection kits, won the state food and drug supervision and administration bureau to issue three kinds of the medical device registration certificate, will be formally clinical popularization and application. 
 
        Hong-yang wang said that the kit is mainly used for pathological diagnosis and classification of liver cancer, especially in the differential diagnosis of benign and malignant liver tumor cases, for clinical liver tumor malignant cases in a timely manner to carry out the individualized treatment and avoid excessive treatment benign cases, has important application value. 
 
 
        Hepatitis b virus carriers in China nearly 100 million people, quite a long time cancer of the liver high-risk situation is very difficult to reverse. In the 1950 s, represented by asnich academician of the old medical break liver surgery area, significantly improved the level of clinical diagnosis of liver cancer in China. But in the early diagnosis of liver cancer, parting, individualized treatment and improve the postoperative survival, is still a crucial problem. 
 
        Beginning in 1997, hong-yang wang group in the domestic application of gene chip study first liver cancer specific sensitive marker gene, isolated from the liver tissue cDNA library GPC3 gene, found that its development is closely related with the incidence of liver cancer, liver cancer in the positive expression rate of more than 80%, is expected to AFP AFP complementary synergy for early diagnosis of liver cancer. In addition, GPC3 benign tumor in the liver or other negative expression in tumor metastasis to the liver of cases, but in the malignant progress of liver cancer in its expression level increased gradually, especially in the AFP negative in liver cancer patients have a higher detection rate, and thus to prompt relapse, metastasis and evaluate the surgical treatment effect has clinical significance. To launch with a fully independent property rights of GPC3 detection kit.